252 related articles for article (PubMed ID: 12960123)
21. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.
Fransén K; Klintenäs M; Osterström A; Dimberg J; Monstein HJ; Söderkvist P
Carcinogenesis; 2004 Apr; 25(4):527-33. PubMed ID: 14688025
[TBL] [Abstract][Full Text] [Related]
22. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
[TBL] [Abstract][Full Text] [Related]
23. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
[TBL] [Abstract][Full Text] [Related]
25. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma.
Lee DA; Cohen JA; Twaddell WS; Palacios G; Gill M; Levit E; Halperin AJ; Mones J; Busam KJ; Silvers DN; Celebi JT
Cancer; 2006 Feb; 106(4):907-13. PubMed ID: 16421887
[TBL] [Abstract][Full Text] [Related]
26. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM
Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154
[TBL] [Abstract][Full Text] [Related]
27. The T1799A BRAF mutation is present in iris melanoma.
Henriquez F; Janssen C; Kemp EG; Roberts F
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):4897-900. PubMed ID: 17962436
[TBL] [Abstract][Full Text] [Related]
28. Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.
Mizumoto Y; Kyo S; Mori N; Sakaguchi J; Ohno S; Maida Y; Hashimoto M; Takakura M; Inoue M
Cancer Sci; 2007 May; 98(5):652-8. PubMed ID: 17388789
[TBL] [Abstract][Full Text] [Related]
29. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.
Knobbe CB; Reifenberger J; Reifenberger G
Acta Neuropathol; 2004 Dec; 108(6):467-70. PubMed ID: 15517309
[TBL] [Abstract][Full Text] [Related]
30. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region.
Amanuel B; Grieu F; Kular J; Millward M; Iacopetta B
Pathology; 2012 Jun; 44(4):357-9. PubMed ID: 22614711
[TBL] [Abstract][Full Text] [Related]
31. KIT gene mutations and copy number in melanoma subtypes.
Beadling C; Jacobson-Dunlop E; Hodi FS; Le C; Warrick A; Patterson J; Town A; Harlow A; Cruz F; Azar S; Rubin BP; Muller S; West R; Heinrich MC; Corless CL
Clin Cancer Res; 2008 Nov; 14(21):6821-8. PubMed ID: 18980976
[TBL] [Abstract][Full Text] [Related]
32. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
33. Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Pavey S; Johansson P; Packer L; Taylor J; Stark M; Pollock PM; Walker GJ; Boyle GM; Harper U; Cozzi SJ; Hansen K; Yudt L; Schmidt C; Hersey P; Ellem KA; O'Rourke MG; Parsons PG; Meltzer P; Ringnér M; Hayward NK
Oncogene; 2004 May; 23(23):4060-7. PubMed ID: 15048078
[TBL] [Abstract][Full Text] [Related]
34. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
35. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
[TBL] [Abstract][Full Text] [Related]
36. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression.
Calistri D; Rengucci C; Seymour I; Lattuneddu A; Polifemo AM; Monti F; Saragoni L; Amadori D
J Cell Physiol; 2005 Aug; 204(2):484-8. PubMed ID: 15702478
[TBL] [Abstract][Full Text] [Related]
37. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma.
Dong J; Phelps RG; Qiao R; Yao S; Benard O; Ronai Z; Aaronson SA
Cancer Res; 2003 Jul; 63(14):3883-5. PubMed ID: 12873977
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
[TBL] [Abstract][Full Text] [Related]
39. Tandem BRAF mutations in primary invasive melanomas.
Thomas NE; Alexander A; Edmiston SN; Parrish E; Millikan RC; Berwick M; Groben P; Ollila DW; Mattingly D; Conway K
J Invest Dermatol; 2004 May; 122(5):1245-50. PubMed ID: 15140228
[TBL] [Abstract][Full Text] [Related]
40. BRAF mutations are associated with some histological types of papillary thyroid carcinoma.
Trovisco V; Vieira de Castro I; Soares P; Máximo V; Silva P; Magalhães J; Abrosimov A; Guiu XM; Sobrinho-Simões M
J Pathol; 2004 Feb; 202(2):247-51. PubMed ID: 14743508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
